SEQUENCE LISTING

<110> Faustman

Hayashi

<120> Methods for Treating and Diagnosing Autoimmune Disease

<130> MGH/Faustman 17633/1030

Attorney Representing Client:

Kathleen M. Williams, Ph.D.

Palmer and Dodge LLP

One Beacon Street

Boston, MA   02108

<140> 09/031,629

<141> 1998-03-27

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fluorogenic

<220>

<221> SITE

<222> (4)

<223> 7-amino-4-methylcoumarin is attached to the

C-terminal Tyr

<220>

<221> SITE

<222> (1)

<223> The N-terminal Leu contains a succinyl

modification

<400> 1

Leu Leu Val Tyr

  1

<210> 2

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fluorogenic

peptide used for degradation assays

<221> SITE

<222> (3)

<223> 7-amido-4-methylcoumarin is attached to the

C-terminal Arg

<220>

<221> SITE

<222> (1)

<223> The N-terminal Leu contains a tert-butyoxycarbonyl

modification

<400> 2

Leu Arg Arg

   1

<210> 3

<211> 3

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Fluorogenic

peptide used for degradation assays

<220>

<221> SITE

<222> (3)

<223> beta-napthylamide is attached to the C-terminal

Glu

<220>

<221> SITE

<222> (1)

<223> The N-terminal Leu contains a carbenzoyx

modification

<400> 3

Leu Leu Glu

1

<210> 4

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Heptapeptide

from the carboxy-terminal domain of RNA polymerase

II large subunit

<400> 4

Tyr Ser Pro Thr Pro Ser

1   5

<210> 5

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Probe for

wild-type kappa B1 sequence

<400> 5

gatctaggga ctttccgctg gggactttcc ag   32

<210> 6

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Probe for

wild-type kappa B2 sequence

<400> 6

gatctcaggg gaatctccct ctccttttat gggcgtagcg   40